Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21698556 | 0.88 | CA2 (0.42) | CA2PLCG1MMP2CA12CA9 | |
| SCHEMBL21300006 | 0.85 | CA2 (0.44) | CA2PLCG1MMP2CA12CA9 | |
| SCHEMBL5403737 | 0.78 | CA2 (0.54) | CA2PLCG1MMP2CA12CA9 | |
| SCHEMBL14255285 | 0.74 | ALDH1A1 (0.61) | CA2PLCG1MMP2CA12CA9 | |
| SCHEMBL8745504 | 0.74 | CA2 (0.50) | CA2PLCG1MMP2CA12CA9 | |
| SCHEMBL714645 | 0.74 | CA2 (0.50) | CA2PLCG1MMP2CA12CA9 | |
| SCHEMBL11814378 | 0.71 | CA2 (0.58) | CA2PLCG1MMP2CA12CA9 | |
| SCHEMBL31713539 | 0.71 | CA2 (0.46) | CA2PLCG1MMP2CA12CA9 | |
| SCHEMBL19670 | 0.70 | LMNA (0.59) | CA2PLCG1MMP2CA12CA9 | |
| SCHEMBL5549033 | 0.70 | LMNA (0.59) | CA2PLCG1MMP2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822331-B2 | Processes for preparing ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-11-03 | — | — | US | disclosed |
| US-10435397-B2 | — | — | 2019-10-08 | — | — | US | disclosed |
| US-10208027-B2 | Processes for preparing ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-02-19 | — | — | US | disclosed |
| EP-2751099-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2017-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822331-B2 | Processes for preparing ATR inhibitors | ATR, ATRIP, CHEK1 | CA2 1969/4885PLCG1 2152/4885MMP2 4725/4885 |
| US-10435397-B2 | — | ATR, ATRIP, TBK1 | CA2 1496/4885PLCG1 2271/4885MMP2 4751/4885 |
| US-10208027-B2 | Processes for preparing ATR inhibitors | ATR, ATRIP, CHEK1 | CA2 1926/4885PLCG1 2102/4885MMP2 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.